CLUE is a Multi-center Trial to Determine how Typically Nociscan’s AI Information Adjustments the Preliminary Therapy Plan for Sufferers With Persistent Low Again Ache
Dr. Justin Kubeck Will Provoke CLUE in New Jersey at Ocean Ache and Backbone in Toms River
BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the situation of continual low again ache, introduced at the moment the growth of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founding father of Ocean Ache and Backbone in Toms River, NJ will be a part of an increasing community of spine surgeons taking part in CLUE to construct a rising physique of information supporting the real-world worth of including Nociscan’s AI generated information to current diagnostic analysis strategies for the therapy of continual low again ache.
Dr. Kubeck is the second surgeon to hitch CLUE because the trial was introduced earlier this month, becoming a member of Dr. John Keller, a neurosurgical spine surgeon in Michigan. The Firm expects a gradual cadence of spine surgeons to hitch CLUE within the coming months to quickly present compelling information to payers as to how continuously Nociscan has a major impression on the decision-making course of through the important stage when surgeons are planning the optimum therapy for his or her affected person.
“I all the time inform new sufferers that we have to see what is smart for his or her particular person circumstances – whether or not it’s treatment, or remedy, or finally, surgical procedure,” defined Dr. Kubeck. “There’s a protocol that I comply with; I don’t ever simply go in and do surgical procedure. For me, growing the very best therapy plan for a person affected person could be very proceduralized. As soon as we decide the issue, then I say, ‘Right here’s what you’ll be able to anticipate, listed below are your choices, and here’s what we’ll resolve collectively.’ Nociscan can be a useful choice help device when evaluating analysis and therapy.”
Globally, 266 million individuals endure from degenerative spine illness and low again ache. Aclarion’s Nociscan answer is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to spotlight if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers important insights into the situation of a affected person’s low again ache.
“Actual world proof is extremely invaluable when evaluating the affect and utility of an rising diagnostic device and when this proof might be quickly secured by skilled surgeons by a trial like CLUE, it turns into a important device for driving early payer protection selections,” acknowledged Ryan Bond, Chief Technique Officer at Aclarion. “We welcome the inbound curiosity that has launched our CLUE trial at a number of websites and encourage others to succeed in out at information@aclarion.com if they’re excited about bringing Nociscan to their sufferers and taking part within the CLUE trial.”
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize scientific therapies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Via a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) information from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers important insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra data, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch accommodates forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic info, equivalent to “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to a variety of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Change Fee. Readers are inspired to overview the part titled “Threat Elements” within the Firm’s Annual Report on Type 10-Okay for the yr ended December 31, 2023, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Change Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post